Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 625-629

  Bradley, Ritu R ^a,b   Lynch, Diana M ^a,b   Iampietro, Mark J ^a,b   Borducchi, Erica N ^a,b   Barouch, Dan H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS CAPSID; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; VACCINATION;

ADENOVIRIDAE; MIRIDAE; MUS;

EID: 84855937196     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06254-11     Document Type: Article

References (15)

1. Barouch DH, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
2. Barouch SVK, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203-5209.
3. Cheng C, et al. 2010. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J. Virol. 84:630-638.
4. Cohen CJ, et al. 2002. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83(Part 1):151-155.
5. Gahéry-Ségard H, et al. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72: 2388-2397.
6. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. 2003. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 77:10366 -10375.
7. Liu J, et al. 2006. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80: 11991-11997.
8. O'Brien KL, et al. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 15: 873-875.
9. Priddy FH, et al. 2008. Safety and immunogenicity of a replicationincompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46:1769 -1781.
10. Roberts DM, et al. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239 -243.
11. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
12. Sumida SM, et al. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179 -7185.
13. Vogels R, et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263- 8271.
14. Xiang Z, et al. 2006. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12:1596 -1599.
15. Youil R, et al. 2002. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13:311-320.